Cover Image
市場調查報告書

胱天蛋白酶8:開發中產品分析

Caspase 8 - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 422316
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
胱天蛋白酶8:開發中產品分析 Caspase 8 - Pipeline Review, H1 2018
出版日期: 2018年01月30日 內容資訊: 英文 61 Pages
簡介

本報告提供以胱天蛋白酶8為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

胱天蛋白酶8 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • BeyondSpring Pharmaceuticals Inc
  • Conatus Pharmaceuticals Inc
  • LG Life Science LTD

藥物簡介

  • emricasan
  • Gene Therapy to Activate FADD for Melanoma
  • nivocasan
  • plinabulin
  • Small Molecule to Activate Caspase 8, 9 for Oncology

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1260TDB

Title:
Caspase 8
(Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H1 2018.

Summary:

Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Caspase 8 - Pipeline Review, H1 2018, outlays comprehensive information on the Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Caspase-8 is a caspase protein, encoded by the CASP8 gene. It binds to the adapter molecule FADD recruits it to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolytic activation.

The active dimeric enzyme is then liberated from the DISC and activates downstream apoptotic proteases. Proteolytic fragments of the N-terminal propeptide (termed CAP3, CAP5 and CAP6) are likely retained in the DISC. Cleaves and activates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. It participates in the GZMB apoptotic pathways. It cleaves ADPRT. Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC.

The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Cardiovascular, Genito Urinary System And Sex Hormones, Hematological Disorders, Immunology, Infectious Disease, Respiratory and Toxicology which include indications Colorectal Cancer, Autoimmune Hepatitis, Breast Cancer, Chemotherapy Induced Neutropenia, Febrile Neutropenia, Glioblastoma Multiforme (GBM), Hepatitis C, Hepatocellular Carcinoma, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Fibrosis, Liver Transplant Rejection, Melanoma, Metastatic Brain Tumor, Multiple Myeloma (Kahler Disease), Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Portal Hypertension, Primary Sclerosing Cholangitis, Pulmonary Fibrosis and Renal Failure.

Furthermore, this report also reviews key players involved in Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61)
  • The report reviews Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Overview
    • Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Companies Involved in Therapeutics Development
    • BeyondSpring Pharmaceuticals Inc
    • Conatus Pharmaceuticals Inc
    • Novartis AG
  • Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Drug Profiles
    • emricasan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate FADD for Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IDN-7314 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MBRI-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plinabulin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Caspase 8, 9 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Dormant Products
  • Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Discontinued Products
  • Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 17, 2018: BeyondSpring to Present Data from Phase 2 Portion of Study 105 Phase 2/3 Trial with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium
      • Dec 14, 2017: BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia
      • Dec 07, 2017: BeyondSpring to Webcast Key Opinion Leader Event in NYC on Dec. 14, 2017
      • Dec 04, 2017: BeyondSpring's Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China
      • Nov 30, 2017: BeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate Superiority
      • Oct 26, 2017: BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia
      • Oct 23, 2017: BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline
      • Oct 20, 2017: Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting
      • Oct 18, 2017: BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco
      • Oct 18, 2017: EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
      • Aug 14, 2017: Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis
      • Jul 06, 2017: China FDA Approves CTAs for BeyondSpring's Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia Prevention
      • Jun 26, 2017: FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
      • Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference
      • Jun 15, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin at 2017 BIO International Convention in San Diego
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018
  • Pipeline by Conatus Pharmaceuticals Inc, H1 2018
  • Pipeline by Novartis AG, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Dormant Products, H1 2018 (Contd..2), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top